oncnursingnews1h
FDA Approves Isatuximab Plus VRd for Newly Diagnosed Myeloma
The FDA approved isatuximab plus bortezomib, lenalidomide, and dexamethasone for patients with newly diagnosed myeloma who ...
oncnursingnews3h
NKT2152 Shows Promising Efficacy in Advanced Clear Cell Kidney Cancer
NKT2152, a novel HIF2a inhibitor, demonstrates significant efficacy in patients with advanced clear cell renal cell carcinoma ...
oncnursingnews7h
ESR1 Testing Is Crucial in Second-line HR+, HER2- Metastatic Breast Cancer
During a Community Case Forum series, breast cancer experts discussed the importance of testing for ESR1 mutations, in ...
oncnursingnews21h
Kathleen Keenan, NP
T-DXd Outranks Treatment of Physicians’ Choice in QOL for HR+/HER2-Low/Ultralow MBC ...
oncnursingnews21h
Danielle Hicks
T-DXd Outranks Treatment of Physicians’ Choice in QOL for HR+/HER2-Low/Ultralow MBC ...